Methods: In this study, we used magnetic resonance (MR) methods to determine the effect of obesity treatment with semaglutide, a GLP-1 receptor agonist, on the liver fat content and selected metabolic variables. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.